Randall Batemen, MD, principal investigator of the research and a neurologist at Washington University in St. Louis, told the New York Times the results were "really crushing."

The National Institute on Aging awarded Wake Forest School of Medicine a five-year grant to examine if a novel PET tracer can help researchers tackle the disease.

Nuclear medicine experts called on the field to work together and share data in order to produce the sample sizes needed for further breakthroughs.

The imaging agent—Myeliviz—will be tested in humans for the first time, and may change the way clinicians diagnose the autoimmune disease.

The approach can help families make more informed treatment decisions, which can be critical for organ donation, according to authors of a new study.

Imaging markers such as breast parenchymal uptake varied greatly between women with benign and malignant lesions, according to a study published in the Journal of Nuclear Medicine.

The findings may offer new targets for researching and treating patients with the condition.

The move delays a restriction on licenses required to export highly enriched uranium for two years.

Researchers may improve heart attack outcomes by zeroing in on the cellular activity that causes long-lasting damage to the heart.

Amyloid plaques have long been the target of Alzheimer’s-focused research, but a new study suggests it may be time to prioritize tau imaging instead.

The go-ahead was granted to the Feinstein Institutes for Medical Research to use Fluorodopa F-18 injections in patients with suspected Parkinson’s syndromes.

Combining fluorodeoxyglucose PET with high-resolution CT can help predict subtypes of early lung adenocarcinoma—a form of cancer that is on the rise.